4. Minimally invasive is more important
Michael Mahoney, CEO of Boston Scientific (NYSE:BSX), thinks medtech companies building minimally invasive tools will have an advantage as health systems move more procedures to outpatient settings:
“It’s a big part of our business now with specific divisions like neuromodulation, urology, peripheral interventions. … Now in a COVID world you’re seeing hospitals … shifting more procedures that are possible to an outpatient setting. And so we think that makes sense, given the fact that we’re a primarily interventional medicine company. … We’re trying to really disrupt surgical with less invasive approaches, especially in our endo business.”